The promoter methylation of O-6-methylguanine-DNA methyltransferase (MGMT) and IDH-1 have been designated as meaningful molecular biomarkers for glioma in the National Comprehensive Cancer Network (NCCN) guidelines [29]. This evidence concerns the gene MGMT and glioma.